Gedeon Richter Plc. together with Sumitomo Pharma America Inc. and Sumitomo Pharma Switzerland, GmbH ('SMPS') announce that the European Commission ('EC') has granted approval of a Type II Variation application for RYEQO® (relugolix 40 mg, estradiol 1.0 mg, and norethisterone acetate 0.5 mg) for the symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. This decision followed a positive opinion from the Committee for Medicinal Products for Human Use ('CHMP') of the European Medicines Agency ('EMA') on 15 September 2023 and is applicable for all Member States in the European Union. RYEQO® was initially approved by the EMA in July 2021 for the treatment of moderate-to-severe symptoms of uterine fibroids in adult women of reproductive age.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
9,550 HUF | +0.79% | +2.96% | +9.14% |
25/03 | Gedeon Richter Plc. Proposes Dividend | CI |
29/02 | Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
9,550 HUF | +0.79% | +2.96% | 4.9B | ||
414 JPY | +1.72% | +15.28% | 1.04B | ||
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+9.14% | 4.9B | |
+19.66% | 43.27B | |
+24.60% | 22.92B | |
+20.29% | 15.43B | |
+13.04% | 12.95B | |
+40.87% | 11.83B | |
-8.39% | 6.91B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+13.13% | 5.55B |
- Stock Market
- Equities
- RICHTER Stock
- News Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt.
- European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of Endometriosis